Besifovir

Summary

Besifovir (CHEMBL329091) is a phase-3 clinical-stage small molecule; indicated across 1 condition including chronic hepatitis b virus infection.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 299.22 Da · C10H14N5O4P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL329091
Name	Besifovir
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5270766
Molecular formula	C10H14N5O4P
Molecular weight	299.22
InChIKey	KDNSSKPZBDNJDF-UHFFFAOYSA-N

SMILES: C1CC1(CN2C=NC3=CN=C(N=C32)N)OCP(=O)(O)O

IUPAC name: [1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethylphosphonic acid

Also known as: Besifovir, Lb80331, BESIFOVIR

Patent coverage: 148 distinct patent families (433 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 421 (97%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
chronic hepatitis B virus infection	3	MONDO:0005366	EFO:0004239

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01937806	PHASE3	UNKNOWN	Phase 3 and Extensional Study of Besifovir
NCT02792088	PHASE3	COMPLETED	Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).